Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2016

View Archived Issues

Vaccibody's study of VB10.16 in CIN recommended to move into phase IIa expansion phase

Ilorasertib enters phase II trials for the treatment of CDKN2A-deficient solid tumors

99mTc-rituximab an effective radiotracer for sentinel lymph node mapping in breast cancer

Novel WNK inhibitor demonstrates promise as antihypertensive agent in vivo

Eli Lilly begins phase II trial of LY-3337641 in patients with rheumatoid arthritis

Generon initiates phase III trial of F-627 to treat neutropenia in breast cancer patients

Lilly generates potent and selective GOAT inhibitors for metabolic conditions

Shire launches Xiidra in U.S.

Tonix Pharmaceuticals will conduct two phase III trials of cyclobenzaprine in PTSD

Neurocrine submits NDA for valbenazine to treat tardive dyskinesia

Janssen describes discovery of P2X purinoceptor 7 antagonists including clinical candidate

European orphan drug designation for ALXN-1007 in GVHD

Mundipharma's European phase III trial of Flutiform in COPD misses primary endpoint

Leap Therapeutics and Macrocure sign definitive merger agreement

PERSIST-2 phase III demonstrates statistically significant improvement in spleen volume reduction

Selenoprotein T gene therapy ameliorates experimental heart failure

NLS Pharma starts enrollment for phase II trial of mazindol

Gradalis doses first patient in Vigil plus durvalumab study

University of Athens, University of California patent PLA2 inhibitors

Amgen reports positive results for phase II trial of denosumab

Tetragenetics forms partnership with top pharma company

NCATS identifies compounds with potential through Zika screening program

Centaurus BioPharma, Jiangsu Chia Tai Tianqing and Lianyungang Ruzhong patent DPP-IV inhibitors

Approval of European patent supporting RHB-104 for multiple sclerosis

Chengdu Institute of Biology identifies sparstolonin B derivatives

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...